C3 Jian Raises $60.5M To End Cavities

Los Angeles-based C3 Jian, which is developing biopharmaceuticals aimed at improving oral healthcare, said Monday that it has raised $60.5M in a Series D financing. The funding was led by Renaissance Holding Company, and also included affiliates of Delta Dental. According to the company, the funds will go towards clinical development of the company's peptide-based, antimicrobial drugs, which are aimed at attacking Streptococcus mutans, a bacterium responsible for dental caries or tooth decay. C3 Jian is led by Todd R. Patrick. More information »